Ocumension Therapeutics (HK:1477) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Ocumension Therapeutics has announced that its new drug application for OT-502, a dexamethasone implant designed to treat postoperative inflammation following cataract surgery, has been accepted by China’s National Medical Products Administration. This single-dose, sustained-release solution is the first of its kind approved by the FDA in the US and has completed phase III clinical trials in China, meeting its primary endpoints. However, the company cautions investors as commercial success is not guaranteed.
For further insights into HK:1477 stock, check out TipRanks’ Stock Analysis page.